Mammalian CEs
Carboxylesterases (EC 3.1.1.1) are members of an a,b-hydrolase-fold family and are found in various mammalian species. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] These enzymes efficiently catalyze the hydrolysis of a variety of ester-and amide-containing chemicals as well as drugs and chemicals to the respective free acids. They are also involved in the detoxification or metabolic activation of various drugs, pesticides, environmental toxicants and carcinogens. Carboxylesterases catalyze the hydrolysis of endogenous compounds, such as short-and long-chain acylglycerols, long-chain acyl-carnitine, and long-chain acyl-CoA esters. 2, [15] [16] [17] [18] [19] [20] [21] [22] We have reviewed the characteristics of CEs in relation to the metabolism of xenobiotics. [23] [24] [25] [26] Multiple isozymes of hepatic microsomal CE exist in various animal species [27] [28] [29] and some of these isozymes are involved in the metabolic activation of certain carcinogens, as well as being associated with hepatocarcinogenesis. 17) It has been suggested that CEs can be classified into five major groups, CES1 to CES5, according to the homology of the amino acid sequence, 23, 25, 26) and the majority of CEs that have been identified to belong to the CES1 or CES2 family.
Striking species differences have also been shown; [28] [29] [30] for example, Inoue et al. 31) showed that esterase activity in the dog intestine is very weak and produced no appreciable active band in disk electrophoresis coupled with the staining of esterase activity. On the other hand, esterase activities were observed in the intestines of other species (human, 25, 30, 31) rat, 30, 31) mouse, 31) guinea pig, 31) rabbit, 31) dog 30, 31) and monkey 30) ) and were found to produce a few active bands in an electrophoretic assay.
It is thought that CEs are one of the major determinants of the pharmacokinetics and pharmacodynamics of ester drugs or ester prodrugs. Since the pharmacological data on ester prodrugs obtained from preclinical experiments are generally used as references for human studies, it is important to clarify the biochemical properties of each CE isozyme, including substrate specificity, tissue distribution, and transcriptional regulation.
This review addresses the significant differences in the molecular structure and function of recently identified CEs, and proposes a novel nomenclature for mammalian CE isozymes based on the nucleotide sequences of the genes encoding the individual isozymes. In addition, the different structure-activity relationships of substrates with each CE family and the genetic polymorphism of CE genes are also described.
Novel Classification and Nomenclature of Mammalian CEs
According to the classification of esterase by Aldridge, 33) the serine superfamily of esterase, i.e., AChE, BuChE and CE, falls into the B-esterase group. CE isozymes were initially classified by their substrate specificities and isoelectric point; however, this classification is ambiguous in overlapping substrate specificities. A single esterolytic reaction is frequently mediated by several kinds of enzyme. Recent studies on esterases, as on other enzymes concerned with xenobiotic metabolism, have afforded evidence of multiple forms.
It seems almost impossible to classify these CE isozymes based on their substrate specificity along the lines of the International Union of Biochemistry (I.U.B.) classification, because the individual hydrolases exhibit properties of CE, lipase or both. Mentlein et al. 16) proposed classifying these hydrolases as "unidentified CEs" (EC 3.1.99.1 to 3.1.99.x). Based on the high homology and similarity of the amino acid sequence alignment of the encoding genes, we tried to classify CE isozymes into five families: CES 1, CES 2, CES 3, CES4 and CES 5 24, 25) (Fig. 1 ). The CES 1 family includes the major form of CE isozymes (more than 60% homology with human CES). Thus, they could be divided into eight subfamilies: CES1A, CES1B, CES1C, CES1D, CES1E, CES1F, CES1G, CES1H. Most of the CES1 families, except CES1G, are mainly expressed in the liver. The CES 1A subfamily includes the major forms of human CEs, 18, 19, 34, [36] [37] [38] and the major isoforms of rat, 9) dog, 19) rabbit 37) and mouse 35) CE. The CES1B subfamily includes the major isoforms of rat, 9) mouse 20) and hamster 47) CE, and CES1C includes the major isoforms of dog, 18, 19) cat 50) and human 38) CE. The CES 1H subfamily includes RL1 (CES1H4), mouse ES 4 (CES1H1) and hydrolase B (CES1H3) and C (CES1H2), which catalyze long-chain acylCoA hydrolysis. 6, 9, 18, 27, 39) Members of the CES 1G family are not retained in ER, which are secreted into the blood from the liver, 8, 35) and these families are all secretary-type CEs. It is interesting that the CES1G family is found in only rats and mice, but not humans, and they are all secretary types of CESs. Although a high level of CES1 activity is detected in the blood of rats and mice, no activity is detected in human blood.
In contrast, the CES2 family is mainly expressed in the small intestine. It includes human intestinal CE (CES2A1), 34, [40] [41] [42] [43] [44] rat CES2 (CES2A10), 22) rat intestinal CE RL4 (rCES2) (CES2A6), 45) rabbit form 2 46) and hamster AT51 (CES2A11). 47) CES3 includes ES-male (CES3A2) and human CES3 (CES3A1). 48, 49) Human CES3 (CES3A1) has about 40% amino acid sequence identity with both CEA1A1 and CES2A1, and is expressed in the liver and gastrointestinal tract at an extremely low level in comparison with CES1A1 and CES2A1. 49) The CES4 family includes CE-like urinary excreted protein (CAUXIN) (CES4A2), which is excreted as a major urinary protein in cat urine.
50) The CES 5 family includes 46.5-kDa CE isozymes, 51) which have a different structure from the structures of isozymes in other CE families. Esterase (ES) 46.5-kDa from mouse liver 52) and amide hydrolase from monkey liver 10) probably belong to this family. These groupings are similar to the results of phylogenic analysis (Fig. 1 ).
Structure and Catalytic Mechanism of CE Isozymes
It has been shown that several proteins in the ER lumen have a common carboxy-terminal sequence, KDEL-COOH, and that the structural motif is essential for retention of the protein on the luminal side of the ER through the KDEL receptor bound to the ER membrane. [53] [54] [55] Ozols 46) and Korza and Ozols 56) established the primary structures of two microsomal esterases purified from rabbit liver and designated them 60-kDa esterase forms 1 and form 2, respectively. These two forms of CE have a consensus sequence for the ER retention tetra-peptide (HTEL or HIEL in the one-letter code) that is recognized on the luminal side of the KDEL receptor. The HXEL-COOH motif is also essential for retention of the protein on the luminal side of the ER through the KDEL receptor bound to ER membrane. [53] [54] [55] Robbi et al. 57) reported cDNA cloning of rat liver CES1B4 (ES-10), and that was the first report to show that cDNA of liver CarbE has the consensus sequence of the ER retention tetrapeptide (HVEL-COOH).
Later, Robbi and Beaufay 58) isolated a cDNA clone of another rat liver CES1D2 (ES-3, egasyn), which encoded the consensus sequence of the ER retention tetrapeptide (HTEL-COOH). The other clone, encoded egasyn, is an accessory protein of b-glucuronidase in liver microsomes. 59) Egasyn is identical to CE, and it binds b-glucuronidase via its CE active site. In rats and mice, the carboxyl terminal amino acid sequence of clone rat CES-60KDa (CES1G1) and mouse Es-N (CES1G2) is HTEHK-COOH, which can not bind to KDEL receptor, and these isozymes are secreted into blood. 35) Carboxylesterases have a signal peptide of 17 to 22 amino acid residues near the N-terminal, including hydrophobic amino acid. In the CES1 family, exon 1 encodes a signal peptide. 60, 61) In the CES1 family, a bulky aromatic residue (Trp) followed by a small neutral residue (Gly) directly precede the cleavage site. 62) Carboxylesterases have four Cys residues that may be involved in specific disulfide bonds. Among them, Cys98 is the most highly conserved residue in many CE isozymes. Cygler et al. 1) reported the important alignment of a collection of related amino acid sequences of esterase, lipase and related proteins based on X-ray structures of Torpedo californicaAChE and Geotrichum candidum lipase.
According to the literature, Ser203, Glu336 and His450 form a catalytic triad, and Gly124-Gly125 may be part of an oxyanion hole (Fig. 2 ). These residues are also highly conserved among CE isozymes. Site-specific mutation of Ser203 to Thr203, Glu336 to Ala336, or His450 to Ala 450 greatly reduced the CE activity towards substrates; therefore, this mutagenesis confirmed the role of Glu336 and His450 in forming a putative charge relay system with active site Ser203. 24) Frey et al. 63) reported that the formation of low barrier hy- drogen bonds between His and Asp (Glu for CE) facilitates nucleophilic attack by the b-OH group of Ser on the acyl carbonyl group of peptide in chymotrypsin. The catalytic triad in the tetrahedral addition intermediate is stabilized by low barrier hydrogen bonds. According to their theory, we speculated that the low barrier hydrogen bond between Glu336 and His 450 facilitates nucleophilic attack by the b-OH group of Ser203 on the carbonyl group of the substrate in CE (Fig. 2) . The mechanism of CE could thus be divided into the following steps: 1) The enzyme substrate complex form, positioning the substrate in the correct orientation for reaction. 2) Hydrolysis of the ester bond starts with an attack by the oxygen atom of the hydroxy group of Ser203 on the carbonyl carbon atom of the ester bond.
3) The hydrogen bonds between the negatively charged oxygen of the tetrahedral intermediate and the N-H group of Gly123 and Gly124 stabilize the negatively charged oxygen (O Ϫ ). This configuration, in which negatively charged carboxyl oxygen is hydrogen bonded to two N-H groups, is called an oxyanion hole.
In the general acid-catalyzed step, the ester bond breaks, and the leaving group picks up a proton from the imidazolium ion of His 450 . The acyl portion of the original ester bond remains bound to the enzyme as an acyl-enzyme intermediate. The tetrahedral transition state is stabilized by the formation of low barrier hydrogen bonds between His450 and Glu336. This low barrier hydrogen bond-facilitated mechanism includes weak hydrogen bonds between the oxyanion (O Ϫ ) and peptide N-H bonds contributed by Gly123 and Gly124, which stabilize the tetrahedral adduct on the substrate side of the transition state (Fig. 2) . Formation of the acyl-enzyme complex in the next step requires removal of a proton from His 450 , so that the tetrahedral intermediate is disrupted in the acyl-enzyme intermediate. When the unbound portion of the alcohol group of the first product of the substrate has diffused away, a second step which the deacylation step is essentially the reverse of the acylation step occurs, with a water molecule substituting for the alcohol group of the original substrate.
It is of interest that the sequences required for the hydrolytic capability at the catalytic triad (Glu, His, Ser) of CE, AChE, BuChE, and cholesterol esterase are highly conserved. This is a common structure of a,b-hydrolase-fold families, which are responsible for the hydrolysis of endogenous and exogenous compounds. Furthermore, these elements are strongly conserved among orthologous CEs of the mouse, rat, rabbit, monkey and human.
A three-dimensional model of human CE has been proposed on the basis of crystal structure coordinates of AChE and overlapping active sites with pancreatic lipase and CE. 64) The modeled structure shares the overall folding and topology of the proteins identified in the recently published crystal structures of the rabbit 65) and human CE. 66, 67) Carboxylesterase has a three-dimensional a,b-hydrolase-fold structure, which is a structural feature of all lipases. 66) In general, the structure of CE may be viewed as a central catalytic domain surrounded by a,b and regulatory domains. 65, 67, 68) In essence, the a,b-hydrolase-fold consists of a central b-sheet surrounded by a variable number of b-helices and accommodates a catalytic triad composed of Ser, His and a carboxylic acid. This suggests that the catalytic function of these proteins is conserved across species.
The catalytic triad is located at the bottom from about a 25 Å deep active site, approximately in the center of the molecule, and is composed of a large flexible pocket on one side of Ser203 and a small rigid pocket on the opposite side.
67) The orientation and location of the active site provide an ideal hydrophobic environment for the hydrolysis of a wide variety of hydrophobic substrates.
67) The small rigid active site pocket is adjacent to the oxyanion hole formed by Gly123-124 and is lined by several hydrophobic residues. 67) Short acyl chains would be easily accommodated within the small rigid pocket. The larger flexible active site pocket is lined by several non-polar residues and could accommodate larger or polycyclic molecules, such as cholesterol. The large pocket is adjacent to a side door secondary pore that would permit small molecules (substrates and reaction products) to enter and exit the active site. 67) Longer acyl chains may be oriented for catalysis in such a way that they extend through the side door. Indeed, the presence of a hydrophobic residue at position 423 in mouse CES1B2 and 425 in human CES1A1 is necessary for efficient hydrolysis of hydrophobic substrates, as a mutation of Met 423 of the related rat lung CE (CES1B4) to Ile increased CE activity towards a more hydrophobic substrate without affecting activity towards short-chain esters. 69) Most CE isozymes are glycoproteins, and the carbohydrate chain is required for the enzyme activity of CEs. 3, 24, 26, 29, 34, 68) Human CES2A1 contains a glycosylation site at two different positions (Asn103 and Asn267), while CES1A1 contains only one glycosylation site at Asn79. This glycosylation site is modified by a carbohydrate chain with first N-acetylglucosamine and terminal sialic acid and appears to be involved in the stabilization of the CES1A1 trimer by packing into the adjacent monomer in its crystal structure. 67) According to the X-ray crystal structure of human CES1, this residue lines the flexible pocket adjacent to the side door. 67) Given the wide range of substrates that CEs are known to hydrolyze, the large flexible pocket confers the ability to hydrolyze many structurally distinct compounds, whereas the rigid pocket is much more selective with regard to the substrates that may be accommodated.
Gene Structure and Regulation of CE Isozymes
Both the murine 26) and human 13, 61) CES1 genes span about 30 kb and contain 14 small exons. Recently, sequencing of the mouse and human genomes has been completed, enabling detailed sequence comparisons. Previously published sequences of individual exons, splice junctions, size of the introns and restriction sites within the murine and human CE genes are consistent with their respective genes sequenced by the mouse and human genome projects. Therefore, the organization of the CE gene is evolutionarily conserved in mice and humans. Previous studies have mapped the human CE gene to chromosome 16 at 16q13-q22. 1. 3,36) This region is syntenic to a region of mouse chromosome 8 at 8C5. The murine CE Es22 60) and Es-N 35) have been previously mapped to chromosome 8. The completion of the mouse genome sequencing project unambiguously demonstrated that the murine CE gene was located on the minus strand of chromosome 8 at 8C5 in a cluster of six CE genes that span 260.6 kb. These six CE genes are presumed to have originated from repeated gene duplications of a common ancestral gene that encoded a CE, 61) and subsequent evolutionary divergence may occur.
Recently, we have identified a mouse liver microsomal acylcarnitine hydrolase, mCES2, as a member of the CES2 family. 45) It has been revealed that this enzyme is significantly induced by di(2-ethylhexyl)phthalate (DEHP) and shows medium-and long-chain acylcarnitine hydrolase activity 45) In addition, we have found that mCES2 is expressed in various tissues with higher levels of expression in the liver, kidney and small intestine. Subsequently, it was shown that three transcription factors, specificity protein (Sp) 1, Sp3 and upstream stimulatory factor 1, could bind to the promoter region of the mCES2 gene, leading to synergistic transactivation of the promoter. 21) Although this mechanism may explain the ubiquitous tissue expression profiles of mCES2, it is unlikely to contribute to the higher levels of mCES2 expression in the liver, kidney and small intestine; therefore, it is thought that another mechanism controls this tissue-specific transcription of the mCES2 gene. 21) More recently, we have shown that hepatocyte nuclear factor-4 alpha (HNF-4a) can strongly enhance mCES2 gene transcription and that the involvement of HNF-4a accounts for the high expression level of mCES2 in the liver. 71) These findings are notable when the physiological roles of mCES2 are studied, since HNF-4a is involved in various hepatic functions, such as glucose, cholesterol and drug metabolism. In addition, we found that bile acid can repress mCES2 gene transcription by repressing HNF-4a-mediated transactivation. 71) In 2008, we isolated and characterized two genes encoding the human CES1A1 (AB119997) and CES1A2 (AB119998), and cloned and sequenced the 5' flanking region of each gene in order to elucidate the structure of the promoter 72) (Fig. 3) . It is noteworthy that both the CES1A1 and CES1A2 genes are located on chromosome 16q13-q22 with a tail-to-tail structure. Comparison of the nucleotide sequences of CES1A1 and CES 1A2 genes revealed about 98% homology in 30 Kbp. There are only six nucleotide differences, resulting in four amino acid differences in the open reading frame, and all of the differences exist in exon 1.
Gene duplication has generally been viewed as a necessary source of material for the origin of evolutionary novelties, and duplicate genes evolve new functions. The majority of gene duplicates are silenced within a few million years, with the small number of survivors subsequently being subjected to strong purifying selection. Although duplicate genes may only rarely evolve new functions, the stochastic silencing of such genes may play a significant role in the passive origin of new species. Since exon 1 of the CES1 gene encodes a signal peptide region, intracellular localization of the CES1 gene product was preliminarily investigated using a signal peptide/EYFP-ER chimera protein-expressing system. It was interesting that the CES1A1 signal peptide/EYFP-ER chimera protein was localized to the endoplasmic reticulum, whereas the CES1A2 signal peptide/EYFP-ER chimera protein was distributed in the ER and cytosol.
On the other hand, CES1A2 mRNA was found to be expressed only in the human adult liver, although CES1A1 is expressed in both the human adult and fetal liver. 72) These results suggested that CES1A1 and CES1A2 have different intracellular localizations and different expression profiles in liver differentiation. We therefore investigated the transcriptional regulation of these two CE genes. Reporter gene assays and electrophoretic mobility shift assays demonstrated that Vol. 35, No. 3, 218-228 (2010) Structure and function of carboxylesterase 223 Sp1 and C/EBPa could bind to each responsive element of the CES1A1 promoter but that Sp1 and C/EBP could not bind to the responsive element of the CES1A2 promoter (Fig. 3) . More recently Fukami et al. 73) reported that the sequences of downstream and upstream of the intron of the CES1A2 gene are identical to those of CES1A1 and CES1A3 genes, respectively. A CES1A1 variant, in which exon 1 is converted to that of the CES1A3 gene (transcript is CES1A2), has recently been identified. It was found that the CES1A2 gene is a variant of the CES1A3 pseudogene (Fig. 3) . The expression level of CES1A1 mRNA is much higher than that of CES1A2 mRNA in the liver. 72) Since CES1A1 is highly variable in the individual liver, 74) it was thought that these results provided information on the individual variation of human CES1.
As shown in Table 1 , human CES1 and CES2 were highly expressed in the liver and lung, and the small intestine and kidney, respectively. Knowledge of these substrate structureactivity relationships and the tissue distribution of CE isozymes is critical for predicting the pharmacokinetics and pharmacodynamics of pesticides.
Possible Role of CE Isozymes in Drug Metabolism
Drug-metabolizing enzymes that are present predominantly in the liver are involved in the biotransformation of both endogenous and exogenous compounds to polar products to facilitate their elimination. These reactions are categorized into phase 1 and phase 2 reactions. CE show ubiquitous tissue expression profiles with the highest levels of CE activity present in liver microsomes in many mammals. [15] [16] [17] 20, 52, 74, [75] [76] [77] [78] [79] CEs are categorized as phase 1 drug-metabolizing enzymes that can hydrolyze a variety of ester-containing drugs and prodrugs. These include angiotensin-converting enzyme (ACE) inhibitors (temocapril, cilazapril, quinapril, and imidapril), 20, 38, 80, 81) anti-tumor drugs (CPT-11 and capecitabin), 37, 41, 49, [82] [83] [84] [85] [86] and narcotics (cocaine, heroin and meperidine). 11, 87, 88) Thus, CEs are one of the most important enzymes involved in prodrug activation, notably with respect to tissue distribution, up-regulation in tumor cells and turnover rates.
We have shown that there are some differences between these families in terms of substrate specificity, tissue distribution, immunological properties, and gene regulation. 27) Analysis of substrate structure versus catalytic efficiency for the ester or carbamate substrates has revealed that a different family of CEs recognizes different structural features of the substrate. For example, the preferential substrates for CES1A1, a human CES1 family isozyme, are thought to be compounds esterified by small alcohols, while those for CES2A1, a human CES2 family isozyme, are thought to be compounds esterified by relatively large alcohols. CES1A1, but not CES2A1, hydrolyzed the methyl ester of cocaine and the ethyl esters of temocapril, meperidine, imidapril and oseltamivir. 20, 38, 80, [89] [90] [91] It was interesting that procainamide inhibited CES1-mediated imidapril hydrolysis. 92) Procainamide is also known as a choline-binding pocket-specific inhibitor 93) and has been reported to competitively inhibit human BuChE. 94) Takai et al. 80) reported that a local anesthetic, procaine, and the anticholinergic drug oxybutynin with large alcohol substitutes are substrates for CES2 but not CES1. Procainamide is also a good substrate for CES2. Because the amino acid sequences at the active site were highly conserved among CES1, CES2 and BuChE, 23) it is reasonable to assume that procainamide inhibits CES1-mediated imidapril hydrolysis.
In contrast to the specificity of CES1 for the methyl ester of cocaine, only CES2 hydrolyzed the benzoyl ester of cocaine.
95) The benzoyl esters of cocaine, heroin and CPT-11 (irinotecan) bearing a small acyl moiety and a bulky alcohol group are good substrates for the CES2 isozyme. Irinotecan is one of the most useful anti-tumor drugs. It was interesting that BuChE hydrolyzed the benzoyl ester of cocaine, and also hydrolyzed CPT-11, but not AChE. [96] [97] [98] CPT-11 is a relatively potent and selective inhibitor of human AChE that has properties of the acute cholinergic toxicity observed in some patients. 99) It has been suggested that although these two CE families exhibit broad substrate specificity for ester, carbamate, or amide hydrolysis, these CE isozymes exhibit distinct catalytic efficiencies that correlate with the relative size of the substrate substituents versus that of the enzyme active sites. Tissue-specific expression of CES1 and CES2 was examined by Northern blots, RT-PCR and real-time PCR analysis.
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Ϫ, undetectable, ϩ, weakly expressed, ϩϩ, moderately expressed, ϩϩϩ, strongly expressed, NT, not tested.
Genetic Polymorphism
Geshi et al. 81) first reported that a single nucleotide polymorphism (SNP), Ϫ816A/C, of the CES1A2 gene is associated with the responsiveness to an angiotensin-converting enzyme (ACE) inhibitor, imidapril, whose activity is achieved by CES1 isozyme. Recently, we re-sequenced the CES1A2 promoter region (ϳ1 kB) in 100 Japanese hypertensive patients. Altogether, ten SNPs and one insertion/deletion (I/D) were identified, among which six SNPs and one I/D residing between Ϫ47 and Ϫ32 were in almost complete linkage disequilibrium (DЈϭ1.00, r2ϭ0.97). 100) They consisted of a minor and a major haplotype, the allele frequencies of which were 22% and 74%, respectively. The minor haplotype possessed two putative Sp1 binding sites while the major haplotype did not have any Sp1 binding site. The minor haplotype had higher transcription and Sp1 binding activities than the major haplotype in vitro.
Later, we studied the relationship between CES1A1 polymorphisms and CES activity in 45 human liver tissues. Namely, six single nucleotide polymorphisms (SNPs), Ϫ75G/T, Ϫ46A/G, Ϫ39A/G, Ϫ21C/G, Ϫ20G/A, Ϫ2G/C and one insertion/deletion (I/D), ϩ71A/del were identified in the promoter region of the CES1A1 gene. The ϩ71 A/del was significantly associated with the conversion efficacy of CPT-11 to SN38 and the level of immunoreactive CES1 protein in the liver microsomes. The ϩ71 A/del was not associated with the CES1A1 mRNA level in the liver, and an in vitro reporter assay indicated that ϩ71 A/del does not affect transcription. These results suggest that CES1A1ϩ71 A/del may account, at least in part, for the individual differences in CE activity in human liver microsomes. This polymorphism of CE genes may be a good candidate for studying the pharmacogenetics of the detoxification of drugs and chemicals, including pesticides
Novel Biomarker of Organophosphate Exposure
The development of a sensitive biomarker which can detect pesticide poisoning at any stage is very important. In 1981, Kikuchi et al. 101) reported that rat plasma b-glucuronidase (BG) activity was increased 2 h post-treatment with organophosphorous pesticides (OPs). Subsequently, it was reported that a complex of BG and egasyn, which is an accessory protein of BG, exists in the liver microsomal membrane. Egasyn was found to be a CEs isozyme. 24, 59) BG is loosely bound to egasyn, and the complex is easily dissociated by OP exposure. Subsequently, several studies reported that intake of OP by the liver causes the release of BG into plasma.
102) Fujikawa et al. 103) reported that a single administration of Ops, including O-ethyl O-4-nitrophenyl phenylphosphonothioate (EPN), acephate and chlorpyrifos and bis(p-nitrophenyl)phosphate (BNPP) as a non-OP to rats led to a 100-fold increase in plasma BG activity over the control. In human studies, InayatHussain et al. 104) reported that plasma BG activity in a group of chronically OP-exposed farmers was significantly increased compared to that in non-OP-exposed controls. In these cases, no significant difference in BuChE activity was detected between the farmers and control groups. Recently, Soltaninejad et al. 105) observed a significant increase in blood BG activity in patients severely intoxicated by OP exposure compared to controls. In 2010, Ueyama et al. 106) reported that 42 male adults were classified into two groups; the first group consisted of 21 pesticide control operators (PCOs) who had not sprayed OPs within 3 days prior to their health check (PCO1), while the second group was composed of 21 PCOs who had sprayed OP insecticides within 3 days prior to their health check (PCO2). According to the monitoring data, plasma BG activity in the PCO2 group was higher than in PCO1. In these cases, no significant decrease in BuChE was observed.
These findings suggested that blood BG can be a more sensitive biomarker of OP exposure than the inhibition of AChE and BuChE activities in humans. We concluded that the crosssectional studies in this paper are useful for monitoring OP exposure in a population of pest control operators
Conclusions and Future Directions
Multiple CEs play an important role in the hydrolytic biotransformation of a vast number of structurally diverse drugs. These enzymes are major determinants of the pharmacokinetic behavior of most therapeutic agents containing an ester or amide bond. Several factors influence CE activity, either directly or at the level of enzyme regulation. In the clinical field, drug elimination is decreased and the incidence of drugdrug interactions increases when two or more drugs compete for hydrolysis by the same CE isozyme.
Exposure to chemicals or lipophilic drugs can result in the induction of CE activity. Several drug-metabolizing enzymes, such as cytochrome P450, UDPGT-glucuronosyltransferase and sulfotransferase have been extensively studied to clarify substrate specificity using molecular cloning and cell expression systems. Consequently, the novel findings obtained reveal that the substrate specificity of CE is, at least in part, explained by differences in the nucleotide sequences of the individual CE isozymes.
It is clear that membrane-bound-type CE isozymes in microsomes are required to possess the KDEL tetrapeptide motif at the carboxy terminal of the molecule. Mammalian CEs have been found to have acyl glycerol, acyl-CoA, and acylcarnitine hydrolyzing activities in vitro; however, the physiological roles of CE remain unclear. To clarify the substrate specificity of each CE isozyme, we have begun to search for the substrate recognition site of each isozyme.
In the present review, we described the substrate specificity and tissue-specific expression profile of CE isozymes; therefore, the successful design of ester-containing drugs will be greatly improved by further detailed analysis of the mechanism of action and substrate recognition sites of CE isozymes in mammals.
In conclusion, the molecular-based information on CEs in this review is useful to understand the multiplicity and substrate specificity of the CE family associated with the efficacy, side effects and toxicity of chemicals.
